Clinical trials: sponsored by Zhejiang Cancer Hospital
Breast Cancer
Pucotenlimab and Anlotinib in Combination With Chemotherapy
A prospective, multicenter, single-arm clinical study enrolling patients with histologically confirmed invasive carcinoma, clinical stage II-III, known PD-L1 status, and treatment-naïve triple-negative breast cancer.
- Trial name
- NCT07896668
- Testing
- LP
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer, Chemotherapy-induced Neutropenia
Mecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer
This prospective, real-world observational registry study will evaluate the effectiveness and safety of mecapegfilgrastim for the prevention of chemotherapy-induced neutropenia in patients with advanced breast cancer receiving…
- Trial name
- NCT07899099
- Testing
- No Prophylactic G-CSF, Short-acting G-CSF, Long-acting G-CSF
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zheng Yabing
Intrahepatic Cholangiocarcinoma (Icc)
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and…
- Trial name
- RAINBOW (NCT07691515)
- Testing
- Gemcitabine, Cisplatin, Tislelizumab
- Where
- 21 sites in China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Cancer
Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
This study evaluates the safety, efficacy, and health economic outcomes of modular robotic-assisted minimally invasive esophagectomy (RAMIE) compared with conventional thoracoscopic minimally invasive esophagectomy (MIE) in…
- Trial name
- mRAMIE2026 (NCT07888140)
- Testing
- Modular Robot-Assisted Esophagectomy, Conventional Minimally Invasive Esophagectomy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Ruijin Hospital
Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB), Hematopoetic Stem Cell Transplantation
G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation
Autologous hematopoietic stem cell transplantation(auto-HSCT) plays an important role in treating hematologic malignancies. Mobilization and collection of peripheral blood stem/progenitor cells is the key to successful autologous…
- Conditions
- Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB), Hematopoetic Stem Cell Transplantation, Hemato-oncologic Patients
- Trial name
- NCT07362810
- Testing
- G-CSF+IL-11, G-CSF Granulocyte-Colony Stimulating Factor
- Where
- 7 sites in China
- Volunteers
- 224 people
- Sponsor
- Fudan University
Pain Syndrome, Dizziness
Postoperative Analgesia Between Paravertebral Block and Epidural Block in Esophageal Surgery
Prevention of postoperative pain is essential for the recovery of esophageal surgery. Epidural analgesia is a traditional and standard perioperative pain management for these patients.
- Conditions
- Pain Syndrome, Dizziness, Vomiting, Itching
- Trial name
- NCT06704698
- Testing
- Liposomal bupivacaine, Bupivacaine Hydrochloride
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Zhejiang Cancer Hospital
Thrombocytopenia, Cancer Treatment-induced Thrombocytopenia
Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)
This study is a prospective, single-center, open-label, single-arm clinical trial to assess the safety and efficacy of umbilical cord blood in cancer treatment-induced thrombocytopenia (CTIT) patients.
- Trial name
- NCT07441720
- Testing
- umbilical cord blood
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhejiang Cancer Hospital
Elderly Patients
Ciprofol EC50 for Inducing Loss of Consciousness in Elderly Patients
ciprofol is a recently introduced novel sedative drug. In comparison to the traditional propofol, ciprofol exhibits a higher affinity for GABA A receptors, approximately 4-5 times that of propofol, and possesses fewer side…
- Trial name
- NCT06253078
- Testing
- Ciprofol dose 0.4mg/Kg, Ciprofol dose 0.3mg/Kg, Ciprofol dose 0.2mg/Kg
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
- Trial name
- NCT06055816
- Testing
- Endostar and Envafolimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer Peritoneal Metastases, Gastric Cancer (GC)
Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
This prospective observational study aims to evaluate the efficacy and safety of anti-PD-1 therapy combined with systemic chemotherapy and intraperitoneal nab-paclitaxel as first-line treatment for patients with advanced gastric…
- Conditions
- Gastric Cancer Peritoneal Metastases, Gastric Cancer (GC), Ascites, Malignant
- Trial name
- NCT07855640
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer (GC), Peritoneal Metastases From Gastric Cancer
Retlirafusp Alfa Plus SOX and Intraperitoneal Nab-Paclitaxel for Advanced Gastric/GEJ Cancer With Malignant Ascites
To evaluate the efficacy and safety of retlirafusp alfa in combination with SOX chemotherapy and intraperitoneal nab-paclitaxel as first-line treatment for advanced gastric/gastroesophageal junction (GC/GEJ) adenocarcinoma with…
- Conditions
- Gastric Cancer (GC), Peritoneal Metastases From Gastric Cancer, Ascites, Malignant
- Trial name
- NCT07855757
- Testing
- Retlirafusp Alfa + SOX + Intraperitoneal Nab-Paclitaxel
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Zhejiang Cancer Hospital
Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer
An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer
This exploratory clinical study evaluates the efficacy and safety of combining benmelstobart (a PD-L1 inhibitor) with anlotinib (a multi-target anti-angiogenic TKI) as a first-line, chemotherapy-free treatment for elderly…
- Conditions
- Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
- Trial name
- BEACON-OLD (NCT07849712)
- Testing
- Benmelstobart Combined With Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Rectal Cancer
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)
The goal of this clinical trial is to learn about whether it is safe to omit dissection of the No.253 lymph nodes in mid and low rectal cancer surgery.
- Trial name
- NCT06146946
- Testing
- Dissection of the No.253 lymph node, Omitting the dissection of the No.253 lymph node
- Where
- 8 sites in China
- Volunteers
- 1,384 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Small Cell Lung Cancer Limited Stage
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
This is a single-arm, prospective, exploratory phase II clinical study. The study enrolled newly diagnosed stage T1-3N0-1M0 resectable limited-stage small cell lung cancer.
- Trial name
- NCT06483282
- Testing
- Adebrelimab, Apatinib Mesylate, Etoposide
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Jin Ying
Postoperative Urinary Retention (POUR)
Electroacupuncture on Postoperative Urinary Retention After Radical Surgery for Cervical Cancer
This is a prospective, blinded, single-center, randomized controlled trial. Investigators will include 208 patients with postoperative urinary retention (POUR) after radical hysterectomy for cervical cancer who have a clear…
- Trial name
- NCT07253194
- Testing
- EA intervention
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Lu Chao
Nasopharyngeal Cancinoma (NPC)
Platinum-Free Regimen in Nasopharyngeal Carcinoma
This study aimed to investigate the efficacy of a platinum-free neoadjuvant regimen (gemcitabine, camrelizumab, endostar, and low-dose radiotherapy) followed by a risk-adapted therapeutic strategy in patients with locally…
- Trial name
- NCT07794488
- Testing
- Endostar (recombinant human endostatin injection)
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Zhejiang Cancer Hospital
Advanced Lung Non-Small Cell Carcinoma
ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC
This study aims to explore the correlation of circulating tumor DNA(ctDNA) and the risk of progression in patients with advanced NSCLC who have long-term benefit from first-line immunotherapy (PFS 12 months)
- Trial name
- CR1STAL (NCT05198154)
- Testing
- ctDNA detection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fang Wu
Depression, Thyroid Cancer
Ganoderma Spores Modulate the Gut-Brain Axis
This study aims to investigate whether Sporoderm-removed Ganoderma lucidum spore powder (RGLS) ameliorates depression in thyroid cancer patients through gut-brain axis modulation, and to elucidate the underlying microbial and…
- Trial name
- NCT07524777
- Testing
- Sporoderm-removed Ganoderma lucidum spore powder (RGLS)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ling Zhiqiang
HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Primary liver cancer is a malignant tumor with a very poor prognosis. Hepatocellular carcinoma(HCC) accounts for approximately 80% of cases.
- Conditions
- HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine, ICG (Indocyanine Green), Overall Survival (All-cause Mortality)
- Trial name
- DAWNbreak-120 (NCT07691645)
- Testing
- Shuganhuazhuo Formula, Targeted therapy, Immunotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xiang-Qian
Small-cell Lung Cancer
A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC
This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of ivonescimab combined with irinotecan liposome for relapsed small cell lung cancer, who progressed on PD-(L)1 -based first-line…
- Trial name
- NCT06478043
- Testing
- ivonescimab, irinotecan liposome
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital